Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth

  • Authors:
    • Yoshinobu Saitoh
    • Takao Setoguchi
    • Masahito Nagata
    • Arisa Tsuru
    • Shunsuke Nakamura
    • Satoshi Nagano
    • Yasuhiro Ishidou
    • Hiroko Nagao-Kitamoto
    • Masahiro Yokouchi
    • Shingo Maeda
    • Akihide Tanimoto
    • Tatsuhiko Furukawa
    • Setsuro Komiya
  • View Affiliations

  • Published online on: November 6, 2015     https://doi.org/10.3892/ijo.2015.3236
  • Pages: 235-242
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

High-dose chemotherapy and surgical intervention have improved long-term prognosis for non-metastatic osteosarcoma to 50-80%. However, metastatic osteosarcoma exhibits resistance to standard chemotherapy. We and others have investigated the function of Hedgehog pathway in osteosarcoma. To apply our previous findings in clinical settings, we examined the effects of Hedgehog inhibitors including arsenic trioxide (ATO) and vismodegib combined with standard anticancer agents. We performed WST-1 assays using ATO, cisplatin (CDDP), ifosfamide (IFO), doxorubicin (DOX), and vismodegib. Combination-index (CI) was used to examine synergism using CalcuSyn software. Xenograft models were used to examine the synergism in vivo. WST-1 assays showed that 143B and Saos2 cell proliferation was inhibited by ATO combined with CDDP, IFO, DOX, and vismodegib. Combination of ATO and CDDP, IFO, DOX or vismodegib was synergistic when the two compounds were used on proliferating 143B and Saos2 human osteosarcoma cells. An osteosarcoma xenograft model showed that treatment with ATO and CDDP, IFO, or vismodegib significantly prevented osteosarcoma growth in vivo compared with vehicle treatment. Our findings indicate that combination of Hedgehog pathway inhibitors and standard FDA-approved anticancer agents with established safety for human use may be an attractive therapeutic method for treating osteosarcoma.
View Figures
View References

Related Articles

Journal Cover

January-2016
Volume 48 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Saitoh Y, Setoguchi T, Nagata M, Tsuru A, Nakamura S, Nagano S, Ishidou Y, Nagao-Kitamoto H, Yokouchi M, Maeda S, Maeda S, et al: Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth. Int J Oncol 48: 235-242, 2016
APA
Saitoh, Y., Setoguchi, T., Nagata, M., Tsuru, A., Nakamura, S., Nagano, S. ... Komiya, S. (2016). Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth. International Journal of Oncology, 48, 235-242. https://doi.org/10.3892/ijo.2015.3236
MLA
Saitoh, Y., Setoguchi, T., Nagata, M., Tsuru, A., Nakamura, S., Nagano, S., Ishidou, Y., Nagao-Kitamoto, H., Yokouchi, M., Maeda, S., Tanimoto, A., Furukawa, T., Komiya, S."Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth". International Journal of Oncology 48.1 (2016): 235-242.
Chicago
Saitoh, Y., Setoguchi, T., Nagata, M., Tsuru, A., Nakamura, S., Nagano, S., Ishidou, Y., Nagao-Kitamoto, H., Yokouchi, M., Maeda, S., Tanimoto, A., Furukawa, T., Komiya, S."Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth". International Journal of Oncology 48, no. 1 (2016): 235-242. https://doi.org/10.3892/ijo.2015.3236